reports
Update: Critical juncture in spinal cord injury
StemCells has reached a critical juncture in its development program with a highly encouraging interim analysis of its Phase II PATHWAY study pointing to promising efficacy in cohort 1 of its human central nervous system stem cells (HuCNS-SC) in lead indication spinal cord injury (SCI). Given limited financial resources, StemCells is realigning operations to focus efforts on the internal funding for key pivotal Phase III SCI trials. New group leadership by way of a recently announced change in C...
Update: Phase II trials underway
StemCells has announced transplantation of the first patient in a recently initiated Phase II trial, evaluating its human central nervous system stem cells (HuCNS-SC) as a treatment for dry age-related macular degeneration (AMD). Progression into the Phase II RADIANT trial was supported by the top-line results of its Phase I/II dose-ranging trial in dry AMD announced in June. Additionally, the company began dosing the first cohort in its Phase II PATHWAY study in cervical spinal cord injuries (C...
Update: On the PATHWAY towards pivotal studies
StemCells is steadily progressing its pipeline of proprietary human central nervous system stem cells (HuCNS-SC), focusing on CNS disorders. Trials in its two lead indications, spinal cord injuries (SCI) and dry age-related macular degeneration (AMD) are now migrating from early and encouraging dose finding and initial efficacy to larger Phase II studies powered for proof of concept. Early findings are expected to begin feeding through in the current year. We believe StemCells' shares offer cons...
Initiation: Poised for Phase II
StemCells’ human neural stem cells (HuCNS-SC) are currently in clinical trials for dry age-related macular degeneration (AMD) and spinal cord injuries (SCI). A Phase II study programme in both indications is underway, following early signs of efficacy in Phase I/II trials. Dry AMD could be a sizeable opportunity (we estimate $2bn in peak sales) and represents the bulk of our overall valuation of StemCells at $189m, or $2.75 per share.
QuickView: Ready to advance into Phase II
StemCells made important progress in Q214 with the completion of enrolment in Phase I/II trials for age-related macular degeneration (AMD) and spinal cord injury (SCI), and released promising interim results in dry AMD. Full results are expected mid-2015. Phase II trials with its HuCNS-SC cells for both indications will be initiated during H214. Additionally, the company completed a $20m capital raise in July, which could provide funding through 2015.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.